Purpose of the study is to answer the question whether confocal laser endomicroscopy (CLE, also named 'optical biopsy') might improve the results of medically necessary neurosurgery to prove practicability, safety and harmlessness of CLE during neurosurgical procedures
In patients requiring neurosurgical oncological Intervention using endoscopic devices, a mini laser probe will be administered through the endoscopic device to characterize in vivo the tissue by thousandfold magnification down to the cellular level (so-called optical biopsy). Magnification is presented to the neurosurgeon in time to better differentiate between healthy and pathological tissue. Post-surgery results of in-vivo Differentiation will then be compared to histocytopathological findings.
Study Type
OBSERVATIONAL
Enrollment
10
Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
Clinic of Neurosurgery, Hospital of Cologne
Cologne-Merheim, North Rhine Westfalia, Germany
post-surgery comparison of in-vivo tissue characterization with ex-vivo histocytopathology
Time frame: duration of hospital stay, an expected average of 7 days
proof of complete removal of pathologic tissue within healthy tissue
Time frame: during surgical procedure, an expected average time of three hours
optimal tumour remission or reduction after 3 months post-surgery proven by respective diagnostic measurements
Time frame: 3 months post surgery
Composite measure of missing iatrogenic damage of healthy neuronal structures and preservation of functionality of healthy tissue
Time frame: individual post-surgery controls, an expected average of up to 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.